SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

8i Acquisition 2 Corp. – ‘DEFA14A’ on 10/6/22

On:  Thursday, 10/6/22, at 8:02am ET   ·   Accession #:  1493152-22-27759   ·   File #:  1-40678

Previous ‘DEFA14A’:  ‘DEFA14A’ on 9/8/22   ·   Next:  ‘DEFA14A’ on 11/7/22   ·   Latest:  ‘DEFA14A’ on 11/14/22

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/06/22  8i Acquisition 2 Corp.            DEFA14A                2:7.4M                                   M2 Compliance LLC/FA

Additional Definitive Proxy Soliciting Material   —   Schedule 14A   —   Rule 14a-12

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: DEFA14A     Additional Definitive Proxy Soliciting Material     HTML     39K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     10K 


‘DEFA14A’   —   Additional Definitive Proxy Soliciting Material


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 30, 2022

 

8i Acquisition 2 Corp.

(Exact Name of Registrant as Specified in its Charter)

 

British Virgin Islands   001-40462   n/a

(State or other jurisdiction

of  incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

c/o 6 Eu Tong Seng Street

#08-13 Singapore 059817

(Address of Principal Executive Offices and Zip Code)

 

Registrant’s telephone number, including area code: +65-6788 0388

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
         
Units consisting of one Ordinary Share, no par value, one Redeemable Warrant to acquire one-half (1/2) of one Ordinary Share, and one Right to acquire one-tenth of an Ordinary Share   LAXXU   NASDAQ Stock Market LLC
         
Ordinary Shares included as part of the Units   LAX   NASDAQ Stock Market LLC
         
Redeemable Warrants included as part of the Units   LAXXW   NASDAQ Stock Market LLC
         
Rights included as part of the Units   LAXXR   NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 C: 
 
 

 

Item 7.01. Regulation FD Disclosure

 

8i Acquisition 2 Corp. (the “Company”) retained and compensated Fundamental Research Corp. to prepare a research report on the Company and EUDA Health Limited. The research report attached hereto as Exhibit 99.1 is being furnished pursuant to Item 7.01 of this Current Report and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits:

 

Exhibit

No.

  Description
99.1   Research Report, dated August 30, 2022
104  

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 C: 
 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: October 6, 2022

 

8i Acquisition 2 Corp.  
     
By: /s/ Meng Dong (James) Tan  
Name: Meng Dong (James) Tan  
Title: Chief Executive Officer  

 

 C: 
 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘DEFA14A’ Filing    Date    Other Filings
Filed on:10/6/228-K
8/30/228-K
 List all Filings 
Top
Filing Submission 0001493152-22-027759   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Apr. 26, 3:24:00.1am ET